Best of ASCO 2025, Boise

Boise, ID US
July 19, 2025 to July 20, 2025

This CME-accredited oncology conference, Best of ASCO 2025, Boise, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2025 ASCO® Annual Meeting (ASCO2025) in June 2025. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2025 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

Organizing Committee: 

Course Director:

Binay Shah, MD, MHA - Binaytara

Conference Chairs:

Andrew Scott Pierson, MD - Saint Alphonsus Regional Medical Center

Silvana Bucur, MD - St. Luke's Medical Center

Learning Objectives

At the conclusion of the activity, participants will be able to:

  • Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  • Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  • Explain how to effectively manage side-effects associated with cancer treatment
  • Review abstracts presented at ASCO® 2025 and discuss their application in clinical settings
Course summary
Available credit: 
  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.
Course opens: 
03/04/2025
Course expires: 
09/20/2025
Event starts: 
07/19/2025 - 8:00am PDT
Event ends: 
07/20/2025 - 12:15pm PDT
Cost:
$350.00

DAY 1 - SATURDAY, JULY 19, 2025

All times below are listed in Mountain Daylight Time (MDT)

07:00 AM – 08:00 AM  Registration, Breakfast, and Exhibits


08:00 AM – 08:05 AM  Welcome


08:05 AM – 09:35 AM  Session 1 - Hematologic Malignancies 

Session Chair:

08:05 AM – 08:35 AM  MDS/Leukemias - Roland Walter, MD, PhD, MS

08:35 AM – 09:05 AM  Multiple Myeloma - Arjun Lakshman, MBBS, MD, MRCP | AHN

09:05 AM – 09:35 AM  Lymphoma & CLL 


09:35 AM – 09:45 AM  Break and Exhibits


09:45 AM – 11:05 AM  Session 2 - General Oncology 

Session Chair: Andrew Scott Pierson, MD

09:45 AM – 10:05 AM  Sarcoma - Vaia Florou, MD, MS

10:05 AM – 10:25 AM  Skin Cancers - Lisa Tachiki, MD

10:25 AM – 10:45 AM  Advances in the Management of Ovarian Cancer - Sabrina Bedell, MD

10:45 AM – 11:05 AM  Management of Cervical and Endometrial Cancers - Recent Updates - Gina Westhoff, MD


11:05 AM – 12.00 AM  Session 3 - Case-Based Discussion

Session Chair: Andrew Scott Pierson, MD

Panelists: 


12.00 AM – 12:15 PM  Access to Cancer Care in LMIC 


12:15 PM – 01:15 PM  Lunch and Exhibits

Product Theater Sponsored by Astellas

*This is a non-CME accredited activity*


01:15 PM – 02:45 PM  Session 4 - Genitourinary Cancer

Session Chair: Umang Swami, MD

01:15 PM – 01:45 PM  Bladder Cancer - Petros Grivas, MD, PhD

01:45 PM – 02:15 PM  Prostate Cancer - Manish Kohli, MD

02:15 PM – 02:45 PM  Kidney Cancer - Umang Swami, MD


02:45 PM – 03:15 PM  Break and Exhibits 


03:15 PM – 04:45 PM  Session 5 - Gastrointestinal Cancer

Session Chair: Ignacio Garrido-Laguna, MD, PhD, MBA

03:15 PM – 03:45 PM  Upper GI Cancer - Glynn Weldon Gilcrease, MD

03:45 PM – 04:15 PM  Hepatobiliary and Pancreatic Malignancies - Ignacio Garrido-Laguna, MD, PhD, MBA

04:15 PM – 04:45 PM  Colorectal Cancer -  Stacey Cohen, MD


04:45 PM – 05:30 PM  Reception and Networking

 

DAY 2 - SUNDAY, JULY 20, 2025

07:00 AM – 08:00 AM  Registration, Breakfast, and Exhibits 


08:00 AM – 09:30 AM  Session 6 - Breast Cancer

Session Chairs: Namita Chittoria, MD & Leila Khaddour, MD

08:00 AM – 08:30 AM  Hormone Receptor Positive Breast Cancer - Arya Mariam Roy, MD

08:30 AM – 09:00 AM  Triple Negative Breast Cancer - Aditya Bardia, MD, MPH, FASCO

09:00 AM – 09:30 AM  HER2-Positive Breast Cancer - Mei Wei, MD


09:30 AM – 10:15 AM  Session 7 - Tumor-Board Style Discussion: Challenging Cases

Session Chair: Clinton Morgan, MD

Case Presenter: Nicholas T. Gorden, MD

Panelists: Sri Harsha Tella, MD


10:15 AM – 10:30 AM  Break and Exhibits


10:30 AM – 12:00 PM  Session 8 - Thoracic Oncology

Session Chairs: Matthew Gumbleton, MD, PhD & Anuhya Kommalapati, MD

10:30 AM – 11:00 AM  Early-Stage Non-Small Cell Lung Cancer - Lei Deng, MD

11:00 AM – 11:30 AM  Metastatic Non-Small Cell Lung Cancer - Rajat Thawani, MD

11:30 AM – 12:00 PM  Small Cell Lung Cancer - Siddhartha Devarakonda, MD


12:00 PM  Adjourn

The Grove Hotel
245 S Capitol Blvd
Boise, ID 83702
United States

A limited number of rooms are reserved at the venue for participants and exhibitors of this conference. Please book your hotel room at the link below by June 16th, 2025 to receive the group rate. 

Best of ASCO Boise - The Grove Hotel

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Conference Chair(s)

Andrew Pierson, MD

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Ignacio Garrido-Laguna

has a financial relationship (Grant Or Contract) with BridgeBio Pharma , Genentech;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline ;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with ABM Therapeutics;.
has a financial relationship (Grant Or Contract) with Sumitomo;.
has a financial relationship (Grant Or Contract) with Tango Therapeutics;.
has a financial relationship (Grant Or Contract) with Revolution Medicine;.
has a financial relationship (Grant Or Contract) with MedImmune;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Sotio;.

Matthew Gumbleton, MD, PhD

has a financial relationship (Patent) with Alterna Therapeutics;.
has a financial relationship (Independent contractor) with MJH Lifesciences ;.
has a financial relationship (Independent contractor) with OMNI Health Media;.

Anuhya Kommalapati, MD

has no relevant financial relationships to disclose at this time.

Clinton Morgan

has no relevant financial relationships to disclose at this time.

Umang Swami, MD, MS

has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Adaptimmune;.
has a financial relationship (Other) with AstraZeneca ;.
has a financial relationship (Other) with Sanofi ;.
has a financial relationship (Other) with ImVax;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Seattle Genetics;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Exelixis;.
Speaker/Topic Presenter(s)

Sabrina Bedell

has no relevant financial relationships to disclose at this time.

Stacey Cohen

has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Agenus;.
has a financial relationship (Independent contractor) with Delcath;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Guardant;.
has a financial relationship (Independent contractor) with Exact Sciences;.
has a financial relationship (Independent contractor) with Incyte;.

Lei Deng, MD

has a financial relationship (Independent contractor) with Bristol Meyer Squibb;.
has a financial relationship (Travel) with MJH Life Sciences;.
has a financial relationship (Independent contractor) with Bristol Meyer Squibb;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Travel) with Merck;.
has a financial relationship (Grant Or Contract) with BridgeBio Oncology Therapeutics;.

Siddhartha Devarakonda, MBBS, MD

has a financial relationship (Other) with Apollomics;.
has a financial relationship (Other) with Daiichi-Sankyo;.
has a financial relationship (Other) with Eli Lilly;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Jazz;.
has a financial relationship (Other) with AstraZeneca;.

Vaia Florou

has a financial relationship (Other) with Incyte ;.
has a financial relationship (Other) with Deciphera;.

Petros Grivas, MD, PhD

has a financial relationship (Professional Services) with Bicycle Therapeutics;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Fresenius Kabi;.
has a financial relationship (Professional Services) with Gilead Sciences;.
has a financial relationship (Professional Services) with Astellas Pharma;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Strata Oncology;.
has a financial relationship (Professional Services) with Immunity Bio;.
has a financial relationship (Professional Services) with Asieris Pharmaceuticals;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with QED Therapeutics;.
has a financial relationship (Grant Or Contract) with Gilead Sciences;.
has a financial relationship (Grant Or Contract) with Acrivon Therapeutics;.
has a financial relationship (Grant Or Contract) with ALX Oncology;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Professional Services) with MSD;.
has a financial relationship (Grant Or Contract) with MSD;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Replimune;.
has a financial relationship (Professional Services) with Foundation Medicine;.

Manish Kohli

has a financial relationship (Travel) with Apollo Hospital Enterprise Limited;.
has a financial relationship (Travel) with Triomics;.

Arjun Lakshman

has no relevant financial relationships to disclose at this time.

Arya Mariam Roy, MD

has no relevant financial relationships to disclose at this time.

Lisa Tachiki, MD

has no relevant financial relationships to disclose at this time.

Rajat Thawani, Assistant Professor of Medicine, Division of Hematology & Oncology, Knight Cancer Institute, OHSU

has a financial relationship (Independent contractor) with Merus;.
has a financial relationship (Independent contractor) with Boehringer Ingelheim;.
has a financial relationship (Independent contractor) with Nuvation Bio;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Briston Myers Squibb;.
has a financial relationship (Independent contractor) with Jannsen ;.
has a financial relationship (Independent contractor) with Pfizer;.

Roland Walter, MD PhD MS

has a financial relationship (Grant Or Contract) with ImmunoGen/AbbVie;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Jazz;.
has a financial relationship (Grant Or Contract) with Kura;.
has a financial relationship (Grant Or Contract) with Celgene/Bristol Myers Squibb;.

Gina Westhoff, MD

has a financial relationship (Other) with Pfizer;.

Acknowledgement of Commercial Support

This activity is supported with Independent Medical Education grants from:

  • AstraZeneca
  • Exact Sciences
  • Novartis

Available Credit

  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.

If you are interested in exhibiting at this meeting or purchasing a badge with your company at our discounted rate for exhibitors, please visit our exhibit page here - https://www.sponsorships.binaytara.org/ASCOBoise

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.